Pfizer Inc. (NYSE: PFE) reported its second quarter 2025 earnings results today. Revenues were $14.7 billion, up 10% year-over-year. Reported net income was $2.9 billion, or $0.51 per share, compared to $41 million, or $0.01 per share, last year. Adjusted EPS grew 30% to $0.78. For the full year of 2025, revenue is expected to […]
Pfizer Inc. (NYSE: PFE) reported its second quarter 2025 earnings results today. Revenues were $14.7 billion, up 10% year-over-year. Reported net income was $2.9 billion, or $0.51 per share, compared to $41 million, or $0.01 per share, last year. Adjusted EPS grew 30% to $0.78. For the full year of 2025, revenue is expected to […]
Pfizer Inc. (NYSE: PFE) reported its second quarter 2025 earnings results today.
Revenues were $14.7 billion, up 10% year-over-year.
Reported net income was $2.9 billion, or $0.51 per share, compared to $41 million, or $0.01 per share, last year. Adjusted EPS grew 30% to $0.78.
For the full year of 2025, revenue is expected to be $61-64 billion. The company raised its adjusted EPS guidance to a range of $2.90-3.10.
